Mentions a 3 month trial might be appropriate.
Liothyronine cost and prescriptions in England
Peter N Taylor
Salman Razvi
Ilaria Muller
John Wass
Colin M Dayan
Krishna Chatterjee
et al.
Show all authors
Published:January, 2019DOI:doi.org/10.1016/S2213-8587(...
PlumX Metrics
Levothyroxine is commonly prescribed for hypothyroidism and its use is steadily increasing.1 A subgroup of patients are dissatisfied on levothyroxine monotherapy2 and in some clinical trial patients have shown a preference for a combination of levothyroxine and liothyronine. With clinical trials not showing clear-cut superiority, combination thyroid hormone therapy remains controversial.3 However, acknowledging the limitations (small size, short duration, inconsistent dosage) of previous studies, specialist society guidance recognises that a trial of liothyronine might be appropriate in selected patients4 and studies of genetic polymorphisms (eg, Thr92AlaD2) might indicate specific patients to target. In 2016, the 28-day National Health Service (NHS) cost of liothyronine in the UK increased dramatically from about £4·50 to £258·19, resulting in widespread patient concern and media coverage.5 By contrast, the cost of levothyroxine has broadly remained the same. Clinicians are under increasing pressure to justify prescriptions and, for many patients, treatment has been discontinued or requires private sourcing. A parliamentary enquiry is ongoing. As these changes in costs occurred uniquely in the NHS, these trends in liothyronine prescribing likely only apply in the UK.
We analysed NHS England open prescribing data6 from Aug 1, 2013, to July 1, 2018, sequentially examining the monthly number and cost of NHS liothyronine prescriptions for each clinical commissioning group (CCG; n=195). CCGs are responsible for commissioning health-care services in their local area. In August, 2013, the median number of monthly liothyronine prescriptions per CCG was 22 (IQR 12–38), falling to 17 (10–30) by July, 2018 (p<0·0001). The most substantial changes in prescribing occurred in early 2016, coincident with substantial rise in costs (figure). The total monthly cost of liothyronine prescriptions in August, 2013, was £758 975; this figure increased by almost ten times to £7 018 679 by July, 2018, despite 122 CCGs prescribing less liothyronine